Pneumonia News and Research

Latest Pneumonia News and Research

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

New information about quality of care available in America's hospitals added to new HHS website

New information about quality of care available in America's hospitals added to new HHS website

Heart attack death rates drop in hospitals; CDC reports increase in colon cancer screening rate

Heart attack death rates drop in hospitals; CDC reports increase in colon cancer screening rate

HQA applauds public availability of hospital quality information at Hospital Compare website

HQA applauds public availability of hospital quality information at Hospital Compare website

Study reveals asthma as a risk factor for pneumonia in children hospitalized for influenza

Study reveals asthma as a risk factor for pneumonia in children hospitalized for influenza

First Edition: July 7, 2010

First Edition: July 7, 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Pay-for-performance program may cause inequalities among healthcare providers

Pay-for-performance program may cause inequalities among healthcare providers

Advanced Life Sciences prices securities offering

Advanced Life Sciences prices securities offering

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

AlphaRx regains all rights to Indaflex from Cypress Bioscience

AlphaRx regains all rights to Indaflex from Cypress Bioscience

Health Canada recommends new pneumococcal vaccine for young children

Health Canada recommends new pneumococcal vaccine for young children

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

HealthGrades study examines mortality rates for patients entering hospitals through emergency departments

HealthGrades study examines mortality rates for patients entering hospitals through emergency departments

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.